Question special

This trial involved biochemical testing in order to compensate patients. When implementing this in a clinical setting, should all patients who receive financial incentives be required to test negative for recent tobacco use? This would make giving payment similar to prescribing certain pain medications, where the patients must pass a biochemical test as part of a contract. On a related note, is agreeing to frequent biochemical testing an incentive to quit smoking, independent of the financial incentives?